{ "items": [ "\n\n
\n \n 27 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nIn a research letter to the British Journal of Surgery (BJS) a team of plastic surgeons reveal the effect of the COVID-19 pandemic on skin cancer surgery in the UK.
\n \n\n\n \n 25 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nPeople with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
\n \n\n\n \n 19 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Gary Collins, Professor Cyrus Cooper, Professor Fiona Powrie and the late Professor Doug Altman have been named on the annual Highly Cited Researchers\u2122\ufe0f 2020 list from Clarivate.
\n \n\n\n \n 13 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Simon has been successful in her Wellcome Trust Investigator Award entitled: \u201cProteostasis and Autophagy in Immune Senescence.\u201d
\n \n\n\n \n 10 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.
\n \n\n\n \n 5 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nThree NDORMS researchers have been awarded new titles in the University of Oxford's 2020 Recognition of Distinction exercise.
\n \n\n\n \n 2 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers from the Universities of Oxford, Nottingham and Zhejiang have found that the precise measurement of joint lining inflammation corresponds well with osteoarthritic knee pain. It's even better when size of the joint is taken into consideration and this should be considered when examining treatment effects in clinical trials.
\n \n\n\n \n 30 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nIn a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.
\n \n\n\n \n 29 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nNDORMS researchers have been awarded funding from the Chan Zuckerberg Initiative to ensure that tendon samples from understudied ethnic groups are included in the Tendon Human Cell Atlas.
\n \n\n\n \n 28 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers review the similarities and differences between OARSI and ESCEO 2019 guidelines for the management of knee OA and provide a narrative to help steer health-care providers through the complexities of non-surgical management of the disease.
\n \n\n\n \n 23 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Marco Fritzsche has joined the Kennedy Institute as the Principal Investigator of the Biophysical Immunology Laboratory (BPI), as part of a joint appointment with the Rosalind Franklin Institute. His lab is leading the development of a lattice light sheet microscope that will significantly advance the study of live cells.
\n \n\n\n \n 20 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nA team from the University of Oxford has visualised how key cells of the immune system lock onto cancerous or infected cells to destroy them. The work was led by the Mike Dustin\u2019s group at the Kennedy Institute of Rheumatology and experts in colorectal and ovarian cancers from across Oxford and computational biologists at the University of Birmingham.
\n \n\n\n \n 19 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nNDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.
\n \n\n\n \n 15 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nA review of public comments on a proposed FDA regulatory framework, for modifications to artificial intelligence and machine learning-based software as a medical device, has found that 63% came from parties with financial ties to industry, and that the majority, 86% did not cite any scientific evidence.
\n \n\n\n \n 8 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nInstitution of Engineering and Technology announces 16 Honorary Fellows to mark its 150th year. Professor Stride was awarded the Fellowship in recognition of her contribution to biomedical engineering and research into treatment of major diseases.
\n \n\n\n \n 7 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nOne of the leading causes of workplace absence, carpal tunnel syndrome, can be treated successfully with decompression surgery without serious complications according to research from NDORMS.
\n \n\n\n \n 6 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nPatients hospitalised with COVID-19 were more likely male, younger and, in both the US and Spain, had fewer comorbidities and lower medication use than hospitalized influenza patients according to a recent study published recently by the Observational Health Data Sciences and Informatics (OHDSI) community.
\n \n\n\n \n 2 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers at the Kennedy Institute review the growing body of literature on the role of the microbiome in colorectal cancer
\n \n\n\n \n 30 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
\n \n\n\n \n 23 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n Main\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor of Orthopaedic and Tropical Surgery and Consultant Orthopaedic and Spine Surgeon Chris Lavy has been awarded a prestigious honorary fellowship by the British Orthopaedic Association (BOA).
\n \n\n